The Therapeutic and Diagnostic Potential of Amyloid β Oligomers Selective Antibodies to Treat Alzheimer’s Disease

Kirsten L. Viola*, Maira A. Bicca¹, Adrian M. Bebenek², Daniel L. Kranz¹, Vikas Nandwana³, Emily A. Waters⁴, Chad R. Haney⁴, Maxwell Lee⁴, Abhay Gupta², Zachary Brahmbhatt², Weijian Huang¹, Ting-Tung Chang⁵, Anderson Peck⁵,⁶, Clarissa Valdez¹, Vinayak P. Dravid² and William L. Klein¹,⁷

¹ Department of Neurobiology, Northwestern University, Evanston, IL, United States, ² Illinois Mathematics and Science Academy, Aurora, IL, United States, ³ Department of Materials Science and Engineering, Northwestern University, Evanston, IL, United States, ⁴ Center for Advanced Molecular Imaging, Northwestern University, Evanston, IL, United States, ⁵ Small Animal Imaging Facility, Van Andel Research Institute, Grand Rapids, MI, United States, ⁶ Laboratory of Translational Imaging, Van Andel Research Institute, Grand Rapids, MI, United States, ⁷ Department of Neurology, Northwestern University, Chicago, IL, United States

Improvements have been made in the diagnosis of Alzheimer's disease (AD), manifesting mostly in the development of in vivo imaging methods that allow for the detection of pathological changes in AD by magnetic resonance imaging (MRI) and positron emission tomography (PET) scans. Many of these imaging methods, however, use agents that probe amyloid fibrils and plaques–species that do not correlate well with disease progression and are not present at the earliest stages of the disease. Amyloid β oligomers (AβOs), rather, are now widely accepted as the Aβ species most germane to AD onset and progression. Here we report evidence further supporting the role of AβOs as pathological instigators of AD and introduce promising anti-AβO diagnostic probes capable of distinguishing the 5xFAD mouse model from wild type mice by PET and MRI.

In a developmental study, Aβ oligomers in 5xFAD mice were found to appear at 3 months of age, just prior to the onset of memory dysfunction, and spread as memory worsened. The increase of AβOs is prominent in the subiculum and correlates with concomitant development of reactive astrocytosis. The impact of these AβOs on memory is in harmony with findings that intraventricular injection of synthetic AβOs into wild type mice induced hippocampal dependent memory dysfunction within 24 h. Compelling support for the conclusion that endogenous AβOs cause memory loss was found in experiments showing that intranasal inoculation of AβO-selective antibodies into 5xFAD mice completely restored memory function, measured 30–40 days post-inoculation. These antibodies, which were modified to give MRI and PET imaging probes, were able to distinguish 5xFAD mice from wild type littermates. These results provide strong support for the role of AβOs in instigating memory loss and salient AD neuropathology, and they demonstrate that AβO selective antibodies have potential both for therapeutics and for diagnostics.

Keywords: Aβ oligomers, Alzheimer's disease, 5xFAD, MRI, PET, diagnostics, therapeutics
INTRODUCTION

General Alzheimer’s Disease

More than 6 million Americans are currently living with Alzheimer’s disease (AD), and Alzheimer’s-related deaths have increased 145% from 2000 to 2019 (Alzheimer’s Association, 2021). The financial burden is even more staggering—Alzheimer’s and other dementias have cost the United States more than $600 billion in medical expenses and unpaid care in 2021 (Alzheimer’s Association, 2021). Despite the great personal and economic burden, progress toward developing effective diagnostics and therapeutics remains slow. Aduhelm® (also known as Aducanumab) was recently approved as a treatment for AD (Investor Relations, 2021), the first in more than a decade, but it still focuses on Aβ elimination rather than specific amyloid β oligomer (AβO) targets. As AD burden is expected to increase drastically with the aging population, improved diagnostics and therapeutics are more urgent now than ever.

Amyloid β Oligomers as a Biomarker for Early Alzheimer’s Disease

The primary pathological hallmarks of Alzheimer’s disease are extracellular amyloid plaques and intraneuronal tangles of hyperphosphorylated tau (Masters et al., 1985). It is well known, however, that amyloid plaques do not correlate well with cognitive decline in AD (Terry et al., 1991; Hsia et al., 1999) and are not present in the earliest stages of the disease (Nyborg et al., 2013). Research from the previous two decades strongly indicates that soluble AβOs, not plaques, are the more appropriate amyloid beta species to target in AD (Ashe, 2020; Hampel et al., 2021).

Amyloid β oligomers are potent neurotoxins that show AD-dependent accumulation in the brain of AD patients (Gong et al., 2003; Kayed et al., 2003; Lacor et al., 2004) and transgenic (Tg) rodent AD models (Chang et al., 2003; Lesne et al., 2006; Ohno et al., 2006). For reviews of other perspectives regarding AD molecular etiology (see Robakis, 2011; Lasagna-Reeves et al., 2012). AβOs begin to accumulate early in AD, decades prior to symptoms, and are widely held to be the neurotoxic instigators of AD (Rodgers, 2005; Gandy et al., 2010; Mucke and Selkoe, 2012). AβOs have been shown to exert their toxic effects by instigating failure of synaptic plasticity and memory (Lambert et al., 1998; Lesne et al., 2006; Townsend et al., 2006). Recently, soluble cortical extracts were examined by ELISA and showed that the ratio of AβO levels to plaque density fully distinguished demented from non-demented patients (Esparza et al., 2013); simply put, those with high AβO to plaque ratios were demented and low AβO to plaque ratios were not.

The 5xFAD Mouse Model

The 5xFAD transgenic mouse is an increasingly used AD model that harbors gene mutations in amyloid β protein precursor (AβPP) (K670N/M671L + I716V + V717I) and presenilins (PS1/2) (M146L + L286V) (Oakley et al., 2006). These mutations are known to increase production of Aβ42, characteristic of familial AD, and exhibit expedited plaque development compared to other transgenic mice (Oakley et al., 2006). The Mutant Mouse Resource Research Center (MMRRC) found that Aβ accumulation occurred at different rates, depending on the breeding background, with mice bred on a B6SJL background developing pathology at a significantly more rapid rate (unpublished, available at MMRRC 5xFAD strain data) than those bred on a C57 background. The 5xFAD mouse model is well characterized for memory impairments (Oakley et al., 2006; Kimura and Ohno, 2009; Girard et al., 2013, 2014; Zhang M. et al., 2021), neuron loss (Jawhar et al., 2012; Oblak et al., 2021), and Aβ plaque accumulation (Devi et al., 2010; Jawhar et al., 2012; Ashe, 2020; Zhang M. et al., 2021). Comprehensive studies on the 5xFAD model have also looked at cholesterol and glucose levels (Oblak et al., 2021), activity levels (Oblak et al., 2021), neuroinflammation-related protein levels (Ou-Yang and Van Nostrand, 2013; Oblak et al., 2021), tau phosphorylation (Kanno et al., 2014), and visual acuity (Zhang M. et al., 2021).

Alzheimer’s Disease Diagnostics

Recommended tests (Alzheimer’s Disease Diagnostic Guidelines | National Institute on Aging)1 for diagnosing Alzheimer’s disease include a standard health evaluation and MMSE evaluations. If indicated, these tests are typically followed with cerebrospinal fluid (CSF) assays for tau and Aβ levels, magnetic resonance imaging (MRI) for brain volume and functionality, and positron emission tomography (PET) scans for Aβ plaques, glucose metabolism, and/or tau fibrils in the brain (Albert et al., 2011; Jack et al., 2011; McKhann et al., 2011; Sperling et al., 2011). These analyses may rule out other dementia etiologies and help to determine disease severity, but they cannot detect AD at its earliest stages or closely predict disease progression, as they do not probe for AD’s earliest biomarkers.

Current Diagnostic Methods in Development

Spinal taps are invasive, but CSF assays show promise (Georganopoulou et al., 2005; Toledo et al., 2013). Nonetheless, assays using CSF analytes have presented challenges with respect to accuracy and reliable disease-state discrimination (Slemmon et al., 2012). More recently, assays for AβO levels in the blood plasma have been developed with promising results (Meng et al., 2019). These assays show a correlation between AβO levels and declining memory scores that appear not to be influenced by age, gender, or ApoE4 status. A promising addition to diagnostic methodology is the detection of AD pathology using targeted in vivo brain imaging. The introduction of PET probes for amyloid plaques has been a great technical advance (Klunk et al., 2004) and has established precedent for the usefulness of brain molecular imaging as a diagnostic tool and for proof

1http://nih.gov
of efficacy studies in drug development (Johnson et al., 2013). Still, these new imaging tools focus on late-stage by-products of AD such as plaques, rather than early stage instigators such as AβOs.

Prior studies using 5xFAD mice have examined early- and late-stage disease development, but none have looked at the progressive development of AβOs in this model. Here, we present an analysis of memory impairment from 2 to 9 months of age and the progressive accumulation of AβOs across the same age-span. Our studies presented here use an AβO-selective antibody to characterize the spatiotemporal development of AβOs in the 5xFAD mouse model and demonstrate a correlation with memory impairment. Strikingly, intranasal inoculation of the AβO-selective antibody rescued memory performance in 6-month-old 5xFAD mice. We demonstrate the capability of detecting AβO pathology in vivo in the 5xFAD mouse by introducing molecular imaging modalities (MRI and PET) with probes for AβOs. We additionally present immunofluorescent evidence of a remarkable association between AβOs and glial fibrillary acidic protein (GFAP)-positive reactive astrocytes in the 5xFAD mice. Taken together, we provide further data implicating AβOs as essential diagnostic indicators and therapeutic targets, and show evidence suggesting a mechanism through which AβOs instigate pathological abnormalities.

**MATERIALS AND METHODS**

**Materials**

ACU193 humanized anti-AβO antibody was a generous gift from Acumen Pharmaceuticals, Inc. Aβ1–42 (TFA preparation) was sourced from multiple suppliers (California Peptide, Peptides International, and American Peptide). Primary hippocampal cultures were prepared from tissue obtained from BrainBits, LLC., using media and reagents also obtained from BrainBits. All chemicals were purchased from Sigma unless otherwise specified.

**Animals**

The 5xFAD Tg mouse model [B6SJL-Tg(APPswFIbOn, PSEN1*M146L*L286V)6799Vas] (Oakley et al., 2006) (Jackson Laboratories) was bred on a non-transgenic background [B6SJLF1/J mice (Jackson Laboratories, IMSR_JAX:100012)]. Aged transgenic and wild-type littermates, 2–20 months old, were used. All mice were kept under a 12/12 h light/dark cycle (7 AM/7 PM) at 22 ± 2°C. Mice had free access to food and water, including during behavioral experiments, were housed at ≤5/cage (NexGen IVC, Allentown) with enriched environment and daily veterinarian assessment, according to NU’s standard procedures. Procedures complied with NIH’s Guide for the Care and Use of Laboratory Animals (NIH publication No. 80-23, 1996) and were approved by IACUC (protocol #IS00004010). Behavioral experiments were conducted between 12 and 6 PM.

For intracerebroventricular (ICV) experiments, B6SJLF1/J mice (Jackson Laboratories, IMSR_JAX:100012) were utilized at ages ranging from 6 months of age (30–50 g).

**Amyloid β Oligomer Incubation and Immunolabeling of Cells**

Cells were incubated at 37°C in conditioned media collected from the cell cultures containing crosslinked AβOs or FAM-AβOs or an equivalent dilution of vehicle. Following incubation with AβOs or vehicle for 60 min, the cells were rinsed rapidly 3 times with warm media then fixed by adding an equal volume of warm 3.7% formaldehyde (in PBS) to the third rinse in each well/dish and allowing it to sit at room temperature (RT) for 5 min. The media/formaldehyde was completely removed and replaced with a volume of 3.7% formaldehyde for 5 min at RT. Cells were blocked in 10% normal goat serum (NGS) in PBS or HBSS for 45 min at RT then incubated overnight at 4°C on an orbital shaker with fluorescent-tagged antibody or anti-AβO probe diluted in blocking buffer. The cells were washed three times for 5 min each with PBS or HBSS. After secondary antibody incubation, coverslips were mounted onto glass slides using ProLong Gold Anti-fade reagent with DAPI (Invitrogen) and imaged using an epifluorescence (TE2000, Nikon), a widefield fluorescence

**Amyloid β Oligomer Antibodies for Therapeutics and Diagnostics**

Unlabeled (AβOs) and fluorescently labeled Aβ oligomers (FAM-AβOs) were prepared essentially according to the protocol published by Klein and colleagues (Lambert et al., 2007; Velasco et al., 2012). Briefly, Aβ1–42 (American Peptide or Peptides International) or FAM-Aβ1–42 (AnaSpec) was dissolved in hexafluoro-2-propanol (HFIP) and distributed into microcentrifuge tubes. HFIP was removed by evaporation and traces removed under vacuum; the tubes were stored at −80°C. For unlabeled AβOs, an aliquot of Aβ1–42 was dissolved in anhydrous dimethyl sulfoxide (DMSO) to ∼5 mM, and diluted in ice-cold Ham’s F12 medium without phenol red (Caisson Laboratories) to 100 μM. For FAM-AβOs, an aliquot of each peptide was dissolved in anhydrous DMSO to ∼5 mM, mixed 5:1 (mol:mol) Aβ: FAM-Aβ, and diluted in ice-cold Ham’s F12 medium without phenol red (Caisson Laboratories) to 100 μM. For both AβO preparations, this solution was incubated at 4°C for 24 h and centrifuged at 14,000 × g for 10 min. The supernatant, defined as the AβO or FAM-AβO preparation, was transferred to a clean microtube and stored at 4°C until use. Protein concentration was determined using Coomassie Plus protein assay kit (Pierce). A modification of this protocol was used to produce crosslinked AβOs (Cline E. N. et al., 2019).

All preparations were tested for quality using SDS-PAGE on a 10–20% Tris-Tricine gel followed by both silver stain and Western blot with NU2 anti-AβO antibody (Lambert et al., 2007; Velasco et al., 2012).
microscope (Leica DM6B, Leica Corp.), or confocal microscope (Leica SP2, Leica Corp).

**Amyloid β Oligomer Intracerebroventricular Administration in Mice**

Intracerebroventricular injections and behavior testing were performed in 4 independent experiments of 13–21 mice each. Littermates were arbitrarily assigned to different injection groups, targeting 5–10 mice/group for statistical power \( n = \frac{(Z_{\alpha/2} \sigma)^2}{\delta^2} \) at \( \alpha = 0.05; \sigma = 10.55 \) and \( E = 6.67 \) derived from pilot studies.

Mice were lightly anesthetized (2% isoflurane) during injection (~1 min). AβOs (1, 10 pmol in 3 µl) or vehicles were administered ICV free-handed (Bicca et al., 2015). Separate needles were used for each vehicle, progressing from low-high ABO concentration to minimize carryover. No analgesics or anti-inflammatory agents were necessary. Mice were monitored constantly for recovery of consciousness and ambulation, then periodically for food-and-water intake until behavior analysis. Needle placement was confirmed by brain dissection after behavioral experiments (euthanization: CO₂ then decapitation).

Mice showing needle misplacement (three mice) or cerebral hemorrhage (two mice) were excluded from analysis; final \( n = 5–7 \) mice/group.

**Novel Object Recognition/Novel Location Recognition Tasks**

Tasks were performed essentially as described (Bicca et al., 2015), to evaluate mouse ability to discriminate between familiar and new, or displaced, objects within an area, measured by object exploration (sniffing, touching). The open-field testing arena was constructed of gray polyvinyl chloride at 21 \( \times \) 21 \( \times \) 12” (W \( \times \) L \( \times \) H), with a 5 \( \times \) 5 square grid on floor and visual cue on wall. 24 h post-injection, mice underwent 6 min sessions of habituation and training, with 3 min between. All sessions were video recorded and analyzed by two researchers blind to experimental groups. During habituation and training, mice were screened for ability to move about the arena and explore the objects, two activities required for accurate memory assessment in subsequent testing sessions. Locomotive inclusion criteria (>100 grid crossings and >15 rearings; evaluated in habituation) were based on extensive previous experiments with the same mouse strain and arena; 3/65 mice did not meet this criterion. During training, mice were placed at the arena center with two objects, which were plastic and varied in shape, color, size, and texture. Exploration inclusion criteria were low exploration (<3 s total) or object preference (>50% of total time for either object); 7 of remaining 62 mice did not meet this criterion.

Hippocampal-related memory function was assessed 24 h post-training by displacing one of the two training objects. Cortical-related memory function was assessed 24 h later by replacing the displaced object with a novel object. Hippocampal-related memory function was re-tested 31–38 days post-injection by displacing the novel object. Memory dysfunction was defined as an exploration of the familiar object for >40% total time. Mice were arbitrarily assessed by cage. The arena and objects were cleaned thoroughly between sessions with 20% (v/v) alcohol to minimize olfactory cues.

**Immunolabeling of Slices**

Free floating 45 µm thick sagittal sections were cut using a Leica SM2010 R sliding microtome and transferred to sterile TBS for storage. Sections were gathered and placed sequentially into wells (~4 per well). Sections were then randomly selected from each well to perform antibody staining using the primary antibodies ACU193 (0.2 µg/ml), Alexa Fluor® 555-conjugated NU4 (0.92 µg/ml), Cy3-conjugated anti-GFAP (1:800, Sigma) and the secondary antibody Alexa Fluor® 633 goat anti-human IgG (1:2000, Invitrogen). Floating slices were rinsed 3 \( \times \) 10 min with TBS and blocked with blocking buffer (10% NGS with 0.3% Triton X-100 in TBS) for 60 min at RT. Slices were then incubated with the respective antibodies in blocking buffer overnight at 4°C with gentle rotation. Sections were washed 3 \( \times \) 10 min in TBS and incubated with secondary antibody for 3 h at RT with orbital agitation in the dark. Secondary was prepared in blocking buffer diluted 10-fold with TBS. Sections were then washed 3 \( \times \) 10 min in TBS, mounted using ProLong Diamond® antifade mounting media with DAPI (Invitrogen) and 24 \( \times \) 60 mm No.1.5 glass coverslips (Thermo Scientific). Z-stacks of the brain sections were collected at 10× or 100× on a Leica SP5 confocal microscope and analyzed with ImageJ.

**Thioflavin S Counterstain**

Thioflavin S (ThioS) counterstaining to NU4 immunofluorescence labeling was performed as previously described (Guntern et al., 1992) with a few modifications (Viola et al., 2015). 5xFAD and WT brains were sliced at a thickness of 50 µm and immunolabeled following the same protocol described above (immunolabeling of slices). Slices were incubated with antibody as described above. The slices were then washed with PBS for five times 5 min each and incubated with 0.002% of ThioS solution in TBS-T (diluted from a stock solution 0.02% of ThioS in distilled water) for 10 min. Slices were then washed three times for 1 min in 50% ethanol and two times in TBS-T for 5 min. The slices were mounted with ProLong Gold Antifade reagent for examination by fluorescence microscopy. Images were acquired at 40× magnification and analyzed by ImageJ software.

**Radiolabeling and Quality Control**

Antibodies, NU4 and non-specific mouse IgG or ACU193 and non-specific human IgG were radiolabeled with positron emitter \(^{64}\text{Cu}\) (\(^{64}\text{CuCl}_2\) in 0.1 M HCl; radionuclide purity >99%, Washington University). For radiolabeling, Wipke and Wang’s method was applied (Wipke et al., 2002). Basically, antibodies mentioned above were conjugated with DOTA-NHS-ester (Macrocyclics, Dallas, TX, United States) and then radiolabeled with \(^{64}\text{Cu}\).

**Conjugation**

Antibody solutions were buffer exchanged with PBS using YM-30 Centricon® centrifugal filters (Millipore, Billerica, MA,
United States). For conjugation, antibodies were reacted with DOTA-NHS-ester in 0.1 M Na₂HPO₄ buffer of pH 7.5 at 4°C for 12–16 h in a molar ratio of DOTA-NHS-ester:antibody = 100:1. After conjugation, the reaction mixture was centrifuged repeatedly (five times) through a YM-30 Centricon® centrifugal filter with 0.1 M pH 6.5 ammonium citrate buffer to remove unconjugated small molecules. The concentrations of purified antibody-conjugate was determined by measuring the absorbance at 280 nm in a UV spectrophotometer.

Labeling
When labeling with ⁶⁴Cu, 1 mg DOTA-conjugated NU4 and 5 mCi (185 MBq) of ⁶⁴Cu as incubated in 0.1 M ammonium citrate buffer, pH 6.5, at 43°C for 1 h. Labeled antibody was separated by a size-exclusion column (Bio-Spin6, Bio-Rad Laboratories).

Quality Control
Radiochemical purity of antibody was determined by integrating areas on the Fast Protein Liquid Chromatography (FPLC) equipped with a flow scintillation analyzer. This analysis was conducted on a Superpose 12 10/300 GL (Cytiva) size-exclusion column and characterized by the percentage of radioactivity associated with the 150 kDa protein peak. The stability of the ⁶⁴Cu radiolabeled mAbs was determined by bovine serum challenge at 44 h.

Conjugation Efficiency
Based on our preliminary data, >90% of conjugation rate, >70% of labeling rate is achieved by following pre-scribed protocol.

Overall Details of Micro Positron Emission Tomography and Micro CT Acquisition
Mice were placed in a 37.5°C heated cage 20–30 min prior to radiotracer injection and moved to a 37.5°C heated induction chamber 10 min prior to injection where they were anesthetized with 2–3% isoflurane in 1000 cc/min O₂. A dose of 40 μg/200 μCi in 100 μL of proposed PET tracers was administered intravenously through the tail vein. Each animal was administered a dose ranging from 30 to 40 μg NU4PET, ACU193PET, or non-immune IgGPET. Probes were administered in a single dose. PET/CT imaging was conducted at 0, 4, 24, and 48 h to measure for changes in distribution and time required for probe clearance or decay.

NU4PET scans were acquired using a Genisys⁴ PET (Sofie Biosciences, Culver City, CA, United States) system and CT scans were acquired using a Bioscan NanoSPECT/CT (Washington, D.C.). When scanning, all mice were placed prone on the bed of the scanner. A 10 min static acquisition was used for PET imaging followed immediately by a 6.5 min CT acquisition both utilizing the mouse imaging chamber from the Genisys⁴. PET reconstruction was performed without attenuation correction using 3D Maximum Likelihood Expectation Maximization (MLEM) with 60 iterations and CT reconstruction used Filtered Back Projection with a Shepp-Logan Filter. PET and CT reconstructions were exported in DICOM image format and fused using custom software developed by the Small Animal Imaging Facility at Van Andel Institute. Fused PET/CT images were analyzed using VivoQuant Image Analysis Suite (invivo, LLC, Boston, MA, United States). Standardized Uptake Values (SUV) were calculated using the mouse body weight and corrected for residual dose in the injection syringe and the injection site, as applicable. The formula used to calculate SUV was

\[
SUV = \frac{\text{Activity}_{\text{tissue}}}{\text{Volume}_{\text{tissue}}} \times \frac{\text{Activity}_{\text{Sample}}}{\text{BodyWeight}_{\text{Sample}}}
\]

Evaluation NU4PET (⁶⁴Cu-NU4) in Amyloid β Oligomers Detection
Two groups (n = 3/group) of 6 months old 5xFAD Tg AD mouse model and two groups (n = 3/group) WT mouse model were used for evaluating the capability of AβOs detection. NU4PET (⁶⁴Cu-NU4) or non-specific IgGPET (⁶⁴Cu-IgG) was injected into each 5xFAD Tg AD mouse model and WT mouse model groups, respectively.

Target (AβOs)–Background (normal tissue) contrasts in PET images were used to distinguish the difference of the capability of AβOs detection between NU4PET and IgGPET in different mouse models. Tracer uptake of high intensity (hot) areas and background tissues in the brain were chosen by drawing regions-of-interest (ROI) along the edges of the areas from the PET images. Average pixel values of each ROIs were acquired and use in Target (AβOs)–Background (normal tissue) contrasts calculation. The formula used to calculate Target-Background contrast was

\[
T - B \text{ Contrast} = \frac{\text{Target Average Pixel Value}}{\text{Background Average Pixel Value}}
\]

Tissue Biodistribution Assessment
Animals were sacrificed immediately after the 44 h post-injection image was acquired. Blood was collected, while brains and 13 other organs and tissues were harvested and weighed. After the blood sample was taken from the heart (~500–1000 μl), 10 ml of saline was injected into left ventricle while the heart was still beating to flush out the residual blood in the organs. Radioactivity in each tissue (cpm) was measured using the γ-scintillation counter. Percentages of the injected dose/gram (%ID/g) were calculated for each tissue/organ by the following formula.

\[
\%ID/g = \frac{(\text{Sample Activity} - \text{Background})}{(\text{Injected Activity} - \text{Background}) \times (\text{Sample weight} \times 100)}
\]

Student’s t-test was conducted to the results between different groups. P < 0.05 is considered statistically significant.

Synthesis of Magnetic Nanostructures
In total, 16 nm magnetite nanoparticles were synthesized by decomposition of iron-oleate at 320°C as described in an earlier report (Park et al., 2004).

Synthesis of Iron-oleate complexes: 10.8 g of iron (III) chloride hexahydrate and 36.5 g sodium olate were dissolved in a mixture
of 60 ml distilled water, 80 ml ethanol and 140 ml hexane and heated at 60°C for 4 h. The organic layer of the biphasic mixture becomes dark, indicating phase transfer of iron (III) ions and formation of iron oleate complex. The resulting dark solution is separated and washed with water three times.

Synthesis of 16 nm magnetite nanoparticles: 18 g of iron oleate complex and 2.58 g of oleic acid were dissolved in 100 g of octadecene at RT and heated to 320°C at a rate of 3.3°C per minute. The reaction mixture is kept at 320°C for 40 min., then cooled down to RT. Resulting nanoparticles are separated from the solution by addition of ethanol and ethyl acetate followed by centrifugation.

Preparation of Dopamine-Tetraethylene Glycol-COOH and Phase Transfer
To make the organic phase synthesized magnetic nanostructures (MNS) suitable for biological application, we functionalized the MNS using an in-house synthesized ligand with carboxylic acid as terminal group (for antibody conjugation), tetraethylene glycol (TEG) as a stabilizer, and nitrodopamine (nDOPA) as an anchor due to its high affinity for Fe (Nandwana et al., 2016).

Synthesis of carboxylate terminated nDOPA ligand and functionalization of the MNS was carried out according to the following protocol. Tetraethylene diacide, N-hydroxysuccinimide (NHS), N,N’-Dicyclohexylcarbodiimide (DCC), nDOPA hydrochloride and anhydrous sodium bicarbonate was dissolved in chloroform under argon atmosphere and stirred for 4 h. Hexane stabilized MNS were added and stirred for another 24 h. The precipitate formed was separated by magnet, dispersed in water and purified by dialysis.

Conjugation of Antibody to Magnetic Nanostructures
The conjugation of buffer stabilized MNS with antibody was done using a conventional carboxyl-amine crosslinking method. We first activated the carboxyl terminated MNS by sulfo-N-hydroxysuccinimide (SNHS) and 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) followed by incubation with corresponding antibody (NU4 or IgG) and N-hydroxysuccinimide (NHS), N,N’-Dicyclohexylcarbodiimide (DCC), nDOPA hydrochloride and anhydrous sodium bicarbonate was dissolved in chloroform under argon atmosphere and stirred for 4 h. Hexane stabilized MNS were added and stirred for another 24 h. The precipitate formed was separated by magnet, dispersed in water and purified by dialysis.

Ab conc. = (total mg added Ab) − (mg Ab in supernatant)

Intranasal Immunization
Mice were anesthetized with isoflurane and then placed on their backs with their heads positioned to maximize the residency time for the delivered material to remain on the olfactory surface. Each naris was administered with ACUMNS or non-immune IgGMNS (10 µl/naris), using a sterile micropipette, slowly over a period of 1 min, keeping the opposite naris and mouth closed to allow complete aspiration of delivered material. Steps were repeated up to five times, maintaining anesthetization in between inoculations, for maximum doses of up to 50 µl/naris.

Magnetic Resonance Imaging of Transgenic and Wild-Type Mice in vivo
Following intranasal inoculation, the probe was allowed to distribute for 4 h before MR imaging was performed according to imaging methodology described in Mundt et al. (2009) T1, T2, and T2* weighted MR images were acquired on a Bruker BioSpec 9.4T magnet, using a 25 mm RF quadrature coil. The in-plane resolution was 75 µm with slice thickness 0.4 mm. T1- and T2-weighted images provide anatomical guidance as well as some localization of the ACUMNS and were acquired with a fat suppressed spin echo sequence (Rapid Acquisition with Relaxation Enhancement, RARE) with the following parameters for T1-weighted (TR = 1000 ms, T生效f = 13.2 ms, rare factor 2, number of excitations, NEX = 4) and for T2-weighted (TR = 3500 ms, T生效f = 58.5 ms, rare factor 4, NEX = 4). T2*-weighted imaging provides more of the localization of the NU4MNS as the iron causes local changes in magnetic susceptibility which T2* weighted images can be sensitive to. A gradient echo sequence was used with the following parameters (gradient echo fast imaging, GEFI; TR = 1200 ms, TE = 5.6 ms, flip angle 35° and NEX = 4).

RESULTS

Memory Dysfunction in 5xFAD Mice Begins Shortly After Amyloid β Oligomer Emergence and Progressively Worsens With Concomitant Amyloid β Oligomer Accumulation in the Hippocampus
Transgenic 5xFAD Novel Object Recognition/Novel Location Recognition
Amyloid plaque development and intraneuronal Aβ42 accumulation are well-established in the 5xFAD transgenic (Tg) mouse model of Alzheimer’s disease. There is robust plaque buildup around 5–6 months of age (Ohno et al., 2006) and intraneuronal Aβ42 accumulation begins as early as 2 months (Oakley et al., 2006). The majority of neuropathological studies in 5xFAD mice have used probes that show amyloid plaque development; how 5xFAD memory impairment coincides with AβOs pathology and development is much less well-characterized. In order to characterize how memory loss correlates with AβOs in the 5xFAD mice, we used the well-established novel object recognition (NOR) task for non-spatial (cortical) memory (Cohen and Stackman, 2015; Denninger et al., 2018) and the novel object recognition (NLR) task for spatial (hippocampal) memory (Antunes and Biala, 2012; Grayson et al., 2015; Denninger et al., 2018). We assessed memory in mice aged 2–18 months. 5xFAD mice showed no evident memory impairment at 2–3 months old (Figure 1A). By 4–5 months old, most transgenic mice showed memory impairment, and by 6–7 months of age memory impairment was apparent in all 5xFAD mice. Importantly, at 4 months old, the majority of 5xFAD mice were impaired in both the hippocampal-dependent and cortical-dependent tasks; there were, however, some mice...
that showed only cortical-impairment. Though less obvious than their Tg littermates, memory loss was detected at 9 months of age in wild-type mice. In summary, we showed that 5xFAD mice first present memory impairment between 3 and 4 months of age. This memory dysfunction afflicts more mice as their age increases until, at 6–7 months, all of the Tg mice are impaired in both hippocampal-dependent and cortical-dependent tasks. These data indicate that memory impairment begins before observed amyloid plaque build-up in the 5xFAD mice.

**Immunohistofluorescence Validation of Amyloid β Oligomer Development**

The development of amyloid plaque pathology is well-established in the 5xFAD mouse model (Oakley et al., 2006; Ohno et al., 2006). Amyloid plaques, however, are no longer considered the most germane Aβ species to AD pathology (Overk and Masliah, 2014; Viola and Klein, 2015; Selkoe and Hardy, 2016; Cline et al., 2018). Characterizing the development of the most relevant species, putatively AβOs, and their association with other pathological changes in AD, such as glial activation or phosphorylated tau (pTau) accumulation, is necessary to better understand disease progression in this model. Sagittal sections of brain tissue, collected and fixed from WT and 5xFAD mice at ages 2, 3, 4, 6, and 8 months of age, were immunolabeled with ACU193 and imaged using confocal microscopy. ACU193, a humanized monoclonal antibody that targets AβOs, has been shown to selectively bind oligomers in vitro (Krafft et al., 2013; Savage et al., 2014) and in the TG2576 mouse model. Here, using ACU193 to probe for AβOs, we show the progressive, spatio-temporal accumulation of AβOs in the hippocampus of 5xFAD mice (Figures 1B–E). AβOs first appear in the subiculum as early as 2 months of age in some mice and are detectable by 3 months in all 5xFAD Tg mice examined. In the transgenic mice, AβOs show a continued accumulation in the subiculum and a spreading of pathology to CA1, CA2 and the dentate gyrus (Figures 1C,D). This timing suggests that AβOs are associated with the observed memory loss.

**ACU193 Detects Amyloid β Oligomers Bound to Primary Neurons With High Specificity**

To validate the specificity of ACU193 for AβOs, the antibody was used in vitro to detect synthetic preparations of oligomers introduced into primary hippocampal neurons in culture (Supplementary Figure 1). Primary hippocampal neurons were treated with cross-linked AβOs, which have been shown to preserve AβO structure in vitro (Cline E. N. et al., 2019), or vehicle control. The cells were subsequently fixed and labeled with ACU193 at increasing dosages. Confocal imaging of the cells showed somatic staining of AβOs in addition to small, nanoscale puncta along dendritic processes (labeled with MAP2). These ACU193-positive puncta are likely AβOs binding to dendritic spines, as seen in previously published work (Lacor et al., 2007; Pitt et al., 2017). Minimal ACU193 labeling was observed on vehicle-treated neurons, indicating its specificity for AβOs.

**ACU193 and NU4 Detect Amyloid β Oligomers**

Additional support for the specificity of ACU193 can be seen in comparing the distribution of ACU193 in brain sections with

---

**FIGURE 1** | Memory dysfunction in 5xFAD mice is substantial by 4 months and is preceded by AβO pathology, detectable by 3 months of age. (A) 5xFAD mice and wild-type littermates were assessed for memory dysfunction using novel location recognition (NLR) (hippocampal-dependent task) and novel object recognition (NOR) tasks (cortical-dependent task). Ages ranged 2–12 months. Data shown here are for the hippocampal-dependent NLR assay. In 5xFAD mice, memory impairment was negligible at 2–3 months, substantial by 4–6 months, and fully penetrant by 6 months of age. Statistical analysis shows that there was no significant difference between the behaviors of the WT mice and the 5xFAD mice at ages 2–5 months, but a statistically significant difference was evident between the recognition task behaviors of the WT mice and 5xFAD mice for ages 6–7 months (p < 0.001) and 6–7 months (p < 0.0001). (B–E) Sagittal brain sections were obtained from 5xFAD and WT mice at ages 2, 3, 4, 6, and 8 months and probed for AβO pathology using a humanized AβO monoclonal antibody. Fluorescent signal was barely detectable at 2 months of age in some mice, more readily detectable by 3 months in all Tg mice, and robust by 6 months. Wild-type littermates presented no signal. Scale bar = 100 µm.

---

Frontiers in Neuroscience | www.frontiersin.org 7 January 2022 | Volume 15 | Article 768646
βOs in the 5xFAD mice. GFAP (Figure 3, magenta) pathology first appeared in the subiculum at 3 months of age concurrent with the first appearance of βOs (cyan) in the subiculum and in close proximity to one another. As the mice aged, GFAP and ACU193-positive pathology concomitantly spread throughout the subiculum and hippocampus (Figures 3B,E). At 9 months, WT mice have minimal GFAP expression (Figure 3C) and no βOs (Figure 3F). These patterns are consistent with possible induction of reactive astrogliosis by βOs. At higher magnification, we observed GFAP-positive reactive astrocytes surrounding an ACU193-positive neuron and projecting their processes onto the cell soma (Figure 3I). In addition, we observed micron-wide ACU193-positive puncta adjacent to astrocytic processes distant from the cell soma.

**Alzheimer’s-Associated Astrocyte Pathology Develops Concomitantly With Amyloid β Oligomers**

To determine whether other Alzheimer’s-related pathologies show developmental regulation or accumulation in the 5xFAD mouse model for AD in association with βOs, we examined immunohistochemical patterns of GFAP, activated microglia (Iba1), and pTau. Immunolabeling for pTau yielded difficult to interpret results which varied amongst the different antibodies for the same epitope and often did not match the literature. Instead, we focused on the inflammatory pathways, stimulated by the strong interest in the involvement of inflammatory responses in AD, in particular a new and growing interest in astrocytes (Wang et al., 2021). Immunolabeling for activated microglia (Iba1) (Supplementary Figure 2) indicated that the WT mice have more ramified microglial cells (resting) while 5xFAD littermates have more amoeboid and activated-shaped microglial cells. Notably, microglial activation was evident at 2 months, with no obvious increase in abundance seen in older animals. In contrast, sagittal sections from 5xFAD or wt mice, aged 3–9 months, were immunolabeled with antibodies against GFAP and co-labeled with ACU193, then imaged by confocal microscopy. We found a marked spatiotemporal association of GFAP pathology with ACU193-positive βOs in the 5xFAD mice. We have previously observed no short-term detrimental impact after inoculation of our βO antibodies into 5xFAD mice, but no studies have been done to determine the long-term positive or negative effects in these mice. To determine the impact of βO-neutralization in 5xFAD mice, 6- and 7-month-old mice were first assessed for memory impairment using the NLR/NOR assay. Mice were then inoculated with ACU193-based probes and

![Figure 2](image-url)
Viola et al. Aβ-O-Antibodies for Therapeutics and Diagnostics

FIGURE 3 | Alzheimer’s-associated astrocyte pathology develops concomitantly with AβOs. Sagittal sections from 5xFAD mice, aged 3–9 months, and their wild-type littersmates were immunolabeled with antibodies against GFAP and ACU193, then imaged on the Leica SP5 confocal microscope at 10× and 100×. Data show that, like the ACU193, GFAP positive glial cells accumulate in an age dependent manner. Scale bar = 100 µm for panels (A–H) ad 10 µm for panel (I).

imaged 24 h later in vivo to ensure target engagement (see next section). The mice were then housed for 30–40 days to monitor any adverse effects or changes in behavior before being reassessed for memory impairment in the NLR/NOR tasks. Strikingly, we found that 6-month-old 5xFAD mice inoculated with the ACU193-based MRI probe had reversal of memory dysfunction, with performance the same as WT controls in the NOR task 30 days post-inoculation (Figure 5). The ACUPET probe similarly ameliorated memory impairment, measured 40 days post-injection. As controls, 5xFAD mice injected with human IgGMNS or IgGPET probe showed no memory improvement. Results from 4 trials of 10–12 animals each show that the ACU193 antibody engages AβOs in vivo, completely reversing memory dysfunction in the 5xFAD mice with no evidence of health issues or side effects. The data establish AβOs as the primary instigators of cognitive dysfunction in 5xFAD mice and support the therapeutic relevance of AβO-selective probes.

Amyloid β Oligomers Imaged in vivo Using ACU193-Based Probes Distinguish 5xFAD From Wild-Type Mice

Magnetic Resonance Imaging Signal From ACUMNS Distinguishes 5xFAD From Wild-Type Mice

Our previous work showed that AβOs can be detected in vivo in the 5xFAD mouse model using antibody-based MRI probes which were conjugated to MNS (Viola et al., 2015). These prior studies used NU4 as the AβO-targeting antibody, which as shown
FIGURE 4 | Intraventricular AβO injection causes memory impairment in wild type mice within 24 h. (A) Wild type mice were tested for performance in recognition tasks beginning 24 h after receiving vehicle (VHC) or AβO injections (AβOs) (10 pmols in 3 µl) into the right lateral ventricle. Mice first were assessed for novel location recognition (NLR) (24 h post-injection) and subsequently for novel object recognition (NOR) (48 h post-injection). AβO-injected mice were unable to perform either recognition task. Statistical analysis shows that there is a statistically significant difference between the recognition task behaviors of the WT mice and the AβO injected mice ($p < 0.0001$). (B) Silver stain (left) and Western blot (right) analysis of the AβOs used for injections and other assays in this study shows preparations contain trimer, tetramer, and higher molecular weight species as has been shown before (Lacor et al., 2007; Lambert et al., 2007; Velasco et al., 2012).

FIGURE 5 | ACUMNS delivered intranasally or ACUPET given four each rescue memory function in 6- to 7-month-old mice. Tg and WT mice, aged 6 months (A), were tested by NLR and NOR assays to ensure predicted behavioral deficits. Mice were then intranasally inoculated with ACUMNS and imaged for probe distribution and detection of AβO pathology in vivo. After imaging, animals were monitored for 30 days for signs of adverse reactions to the probe (none detected), then re-tested by NOR. The 6-month-old animals showed a significant recovery of memory impairment 30 days after inoculation. Human IgG MNS showed no impact on memory recovery. (B) To test the impact of the ACUPET probe on memory function, Tg and WT mice, aged 7 months, were tested by NLR and NOR assays prior to imaging as before. Mice were then injected, via tail vein, with ACUPET or non-specific IgGPET and imaged for up to 24 h to monitor probe distribution. After imaging, animals were monitored for 40 days for signs of adverse reactions to the probe. Animals were re-tested by NOR at 40 days recovery. 5xFAD animals injected with ACUPET showed a persistent recovery of memory impairment that was not seen in the 5xFAD animals injected with IgGPET. ACU-based probes have no impact on wt behavior. Results are representative of four separate trials that showed beneficial impact of these antibody-based probes on memory.

above, binds similarly to ACU193. Here we show that ACU193 can also be developed into a molecular probe for AβO detection in vivo. After baseline imaging by MRI, 12-month-old mice were intranasally inoculated with MNS-conjugated ACU193 and allowed to recover overnight (about 16 h) before imaging again (Figure 6). MRI data shows an accumulation of the ACUMNS probe in the hippocampus and cortex of the 5xFAD mice that is absent in WT controls. ImageJ quantification of signal intensity in the hippocampi of inoculated mice shows a ~30-fold increase in 5xFAD mice over their WT littermates. Using the ACUMNS probe in 18-month-old mice showed similarly robust AD-dependent MRI signal in the hippocampus of the 5xFAD animals, but signals obtained in younger animals (6-months old) were less consistent. These data add to previous studies with the
NU4 probe and show that non-invasive *in vivo* imaging of AβOs is possible using the ACUMNS probe, suggesting its potential diagnostic value and ability to confirm target engagement.

**Development of an ACU193-Based Positron Emission Tomography Imaging Probe for Early Amyloid β Oligomer Detection**

While the spatial resolution of MRI is excellent, its sensitivity is lower than other imaging modalities such as PET. Given PET sensitivity is at least 100 times greater than MRI, we thought it might detect very low levels of AβOs during early stages of AD development. ACU193 was conjugated to DOTA, a chelator, as the initial step in the PET probe development. To ensure that this conjugation did not interfere with the antibody’s ability to target AβOs, sagittal brain slices from 5xFAD mice were probed with the ACU193-DOTA probe and counterstained with ThioS for amyloid plaques (*Supplementary Figure 3*). Results show that ACU193-DOTA detected AβOs in the 5xFAD brain and did not co-localize with ThioS, consistent with previously obtained results showing that ACU193 does not bind amyloid plaques cores (Cline E. et al., 2019).

**ACUPET Detects Pathology in the Brains of 4-Month and Older 5xFAD Mice**

The next step was to determine if radiolabeled ACU193-DOTA (ACUPET) detects AD-related AβOs in the 5xFAD mouse brain at an early age. ACU193-DOTA was incubated with ⁶⁴Cu and free isotopes were removed prior to tail vein injection into mice of either 4 or 18 months old, Mice were then imaged at 1, 4, and 24 h post-injection for ACUPET distribution. At 4 h post-injection, ACUPET accumulation in the brain was detectable, but not robust. By 24 h, accumulation of the ACUPET probe in the brains of the 5xFAD animals was evident in both the 4-month-old animals (*Supplementary Figure 4A*) and the 18 month-old animals (*Supplementary Figures 4B–D*). Animals at 6, 7, 8, and 12 months were also examined and similarly were able to distinguish 5xFAD from WT mice (data not shown).

**Amyloid β Oligomers Are Specifically Detected in vivo by NU4PET**

**NU4-Based Positron Emission Tomography Probe Development**

Given the success of the NU4-based MRI probe (Viola et al., 2015), an NU4-based probe was synthesized for PET imaging. NU4 was conjugated to DOTA and tested to ensure that this conjugation did not interfere with the antibody’s ability to target AβOs. Primary hippocampal neurons, pre-treated with fluorescently conjugated AβOs (FAM-AβOs) and were probed with NU4-DOTA (*Supplementary Figure 5*). Data show that nearly all FAM-AβOs (magenta) were also labeled with the NU4-DOTA probe (co-localization seen as dark blue) and no free NU4-DOTA (cyan) was detected. Vehicle treated cells showed no NU4-DOTA binding. Data confirm the specificity of the NU4-DOTA probe for AβOs, necessary for its use for *in vivo* imaging.

**NU4PET Detects Alzheimer’s Disease-Related Pathology in vivo in 5xFAD Mice, Distinguishing Them From Wild-Type**

Validation of the AβO-PET probes as effective for early AD diagnostics requires verification that they produce an *in vivo* signal that depends on the presence of AβOs. To validate our new probe, NU4 (Lambert et al., 2007; Acton et al., 2010) and non-specific IgG antibodies were conjugated to DOTA and then radiolabeled with positron emitter ⁶⁴Cu using Wipke and Wang’s method (Wipke et al., 2002). Our next step was to image for AβOs by PET following probe delivery. Animals (12 total), 7 months of age, were injected via tail vein with either NU4PET or IgGPET and then imaged at *T* = 1, 2, 4, 8, 20, 30, 40, and 44 h after injection. After 44 h, the animals were euthanized and their brains removed for a final *ex vivo* image of all 12 brains simultaneously (3 animals per group). Results showed the NU4PET specifically identified 5xFAD animals (*Figure 7*). No signal was detected in all three control groups (5xFAD with IgGPET; WT with NU4PET; and WT with IgGPET).
The fraction of NU4PET probe retained (Supplementary Figure 6) showed good uptake into the brains of the 5xFAD mice but not the WT littermates (quantification of uptake; see section “Materials and Methods”). For all mice, the IgGPET probe showed negligible signal. Quantification showed uptake into the brain was comparable to levels of uptake seen with the commercially available Pittsburgh Compound B (PIB) tracer (Mathis et al., 2003; Klunk et al., 2004). To corroborate the presence of AβOs in the animals used for these studies, we analyzed the brain tissue with immunofluorescence. After final PET imaging, the brains were fixed and stored in 10% sucrose until no longer radioactive. Brains were then sliced sagittally at PET imaging, the brains were fixed and stored in 10% sucrose analyzed the brain tissue with immunofluorescence. After final examination of soluble cortical extracts by ELISA found a link between the ratio of AβOs and fibrils with disease. “The ratio of AβO-Antibodies for Therapeutics and Diagnostics

DISCUSSION

Deaths from Alzheimer’s disease, the most common form of dementia, continue to grow and drive the increased focus on developing effective diagnostics and therapeutics for AD. Past focus on amyloid plaques has yet to provide an effective therapeutic, leading to a rise in non-amyloid based strategies (Cummings et al., 2021). Nonetheless, despite poor success in the past, interest in targeting Aβ-derived toxins remains high. It now appears, however, that targeting toxic Aβ oligomers rather than Aβ fibrils is the appropriate strategy for developing disease modifying treatments and early diagnosis (Hillen et al., 2010; Goure et al., 2014; Gibbs et al., 2019). In this study, we confirm that AβOs can induce memory dysfunction in wild type mice and that AβOs in 5xFAD transgenic mice build up in a manner concomitant with memory dysfunction. We show that targeting the buildup of AβOs in the 5xFAD mice with AβO-selective antibodies rescues memory performance. Together, these findings further substantiate the hypothesis that memory dysfunction is driven by AβOs. Developmental data show as well an intriguing spatiotemporal association between buildup of AβOs and GFAP-positive astrocytes. This link is intriguing given recent studies indicating an important role for astrocytes in memory loss (Huang et al., 2017; Monterey et al., 2021; Preeti et al., 2021) and in microglia pathology (Süß and Schlauchetzki, 2020; Streit et al., 2021). Importantly, we demonstrate that antibodies targeting AβOs can be used as brain imaging probes to identify animals with AD pathology, indicating the potential of AβO-selective antibodies for diagnostics as well as therapeutics.

While interest increases in alternatives to the amyloid hypothesis, we are still left with no effective diagnostic tools for identifying AD at its earliest stages when therapeutics have the greatest impact. Currently recommended tests may rule out other dementia etiologies and help to determine disease severity, but they cannot detect AD at its earliest stages or closely predict disease progression. While AD diagnosis has significantly improved with the incorporation of a multiple assay evaluation currently being recommended, the tests still cannot predict disease progression or diagnose AD at its earliest stages because they are not quantifying the earliest biomarkers of the disease. However, alternative detection assays are being developed. Pre-tangle Tau, thought to be the toxic form of tau, has now been detected in MCI and AD and has been found to be one of the earliest tau lesions that correlates with cognitive status (Mufson et al., 2014). Synapse loss (Bastin et al., 2020; Buchanan et al., 2020; Mecca et al., 2020; Pereira et al., 2021), changes in hormone levels (Cheng et al., 2021), changes in blood biomarker levels (Guzman-Martinez et al., 2019; Montoliu-Gaya et al., 2021), electroencephalogram (EEG) readings (Hulbert and Adeli, 2013; Lin et al., 2021), retinal assays (Ashok et al., 2020; Mirzaei et al., 2020), and changes in specific protein levels (Buchanan et al., 2020; Colom-Cadena et al., 2020) are some of the myriad assays being developed to try to detect AD earlier and predict when and if the change from mild cognitive impairment (MCI) to AD will occur (Zhang T. et al., 2021). All of these new developments are focused toward enabling earlier therapeutic intervention when chances for success would be greatest.

Amyloid β oligomers as a diagnostic resource are currently unavailable. CSF assays show promise (Georganopoulos et al., 2005; Savage et al., 2014), but spinal taps are invasive and assays using CSF analytes have presented challenges with respect to accuracy and reliable disease-state discrimination (Slennon et al., 2012). Other assays for AβO levels are under development and show promise as well (Meng et al., 2019). For example, AβO quantification in blood plasma shows a correlation between AβO levels and declining memory scores that appear to not be influenced by age, gender, or ApoE4 status. Recently, the examination of soluble cortical extracts by ELISA found a link between the ratio of AβOs and fibrils with disease. “The ratio of AβO levels to plaque density fully distinguished demented from...
non-demented patients, with no overlap between groups in this derived variable.” (Esparza et al., 2013).

Because AβOs are regarded as the first toxin to appear in disease progression, they should provide an excellent target for diagnostic imaging (Hefti et al., 2013; Goure et al., 2014). The usefulness of targeting AβOs is indicated by human neuropathology studies in which AβOs initially appear bound to discrete neurons, localizing to synapses in dendritic arbor (Lacor et al., 2004) through putative association with clustered cell surface receptors (Ferreira and Klein, 2011). FAM-AβOs bind at discrete sites on dendrites, showingatable, concentration-dependent synaptic binding (Viola et al., 2015), further suggesting their potential as a suitable target for an antibody-based diagnostic probe. Pronucleon imaging used engineered peptides that deliver a readout when associated with beta-rich Aβ fibers and oligomeric Aβ (Nyborg et al., 2013).

Several PET probes have also been developed including a probe from curcumin 18F (Rokka et al., 2014), a probe created by modifying 6E10 antibody with PEG and 64Cu that distinguished Tg from control mice (McLean et al., 2012), and a probe developed from an 124I-labeled mAb158 against Aβ protofibrils (Magnusson et al., 2013). Still, none of these probes specifically target AβOs.

Previously, we described a molecular MRI probe that is targeted against AβOs (Viola et al., 2015). Based on the success of our initial MRI probe and the antibody-based probes being explored by others, it follows that AβO-specific antibodies can be used to target probes and provide better signal-to-noise ratios.

Here we showed that anti-AβO antibodies can be used to develop molecular MRI ad PET probes that distinguish WT mice from their 5xFAD littermates at ages as early as 4 months old. These probes have proven to be non-toxic over the periods examined and, in fact, showed in vivo efficacy. These studies, however, are limited to the 5xFAD mouse model for AD and have not yet been tested in other animal models or in human subjects. Our paper in essence establishes proof of concept that oligomers can be detected by antibody-based probes for PET and MRI. This is a first step, and a great deal of work remains. A case in point, while ex vivo PET imaging is robust in its ability to distinguish AD from control brains, the conditions for in vivo imaging require significant optimization.

Early diagnostics are critical to combating this devastating disease, but without effective therapeutics, they have limited value. The first FDA-approved drug to treat Alzheimer’s disease (AD) in nearly two decades, Aduhelm®, shows a preferential affinity for all aggregated forms of amyloid beta (Aβ), rather than targeting only the toxic AβOs. Currently, there are more than 126 agents in clinical trials, with most aimed at disease modification (Cummings et al., 2021). While less than 10% of these target Aβ, there remains evidence that Aβ is a significant target for therapeutic development. Lowering AβO levels by enhancing fibril formation has been shown to be protective (Mucke et al., 2000). This is supported by previous antibody-based studies (Lambert et al., 2007; Hillen et al., 2010; Xiao et al., 2013; Dorostkar et al., 2014; Silverman et al., 2018; Gibbs et al., 2019). The data presented here importantly show that AβO-selective antibodies rescue memory performance in a widely used AD model. These antibodies, which have been modified for use in brain imaging of AβO, show great promise as potential agents for AD therapeutics and diagnostics; the potential of one AβO-selective antibody is now being assessed in a recently begun clinical trial.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

ETHICS STATEMENT

The animal studies were reviewed and approved by Northwestern University Institutional Animal Care and Use Committee.

AUTHOR CONTRIBUTIONS

KV and DK contributed to the design, data collection, data analysis, and writing. MB, AB, EW, CH, ML, AG, ZB, WH, T-TC, AP, and CV contributed to the design, data collection, and data analysis. VN contributed to the experimental design and provided materials. VD contributed to the experimental design and supplied materials. WK contributed to the experimental design, data analysis, and writing. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported in part by NIH grants (R41AG054337, R21AG045637, and RF1AG063903 to WK). EW is supported by grant number 2020-225578 from the Chan Zuckerberg Initiative DAF, an advised fund of Silicon Valley Community Foundation. Microscopy was performed at the Biological Imaging Facility at Northwestern University (SCR_017767), graciously supported by the Chemistry of Life Processes Institute, the NU Office for Research, the Department of Molecular Biosciences and the Rice Foundation. MRI and PET/CT imaging work was performed at the Northwestern University Center for Advanced Microscopy Imaging (SCR_021192), graciously supported by the Chemistry of Life Processes Institute, the NU Office for Research. Imaging generously supported by NCI CCSG P30 CA060553 awarded to the Robert H. Lurie Comprehensive Cancer Center. Imaging work was performed at the Northwestern University High Throughput Analysis Lab, graciously supported by the Chemistry of Life Processes Institute, the NU Office for Research.

ACKNOWLEDGMENTS

We would like to thank Samuel C. Bartley, Elizabeth A. Johnson, Matthew Perkins, Jake Vitrofsky, Alex L. Qin,
REFERENCES

Acton, P. Q., An, Z. A., Bet, A. J. L., Breese, R. Q., Chang, L. W., Dodson, E. C. S., et al. (2010). Anti-ADDL Antibodies and Uses Thereof. United States Patent Application 11/256332. Washington, DC: U.S. Patent and Trademark Office.

Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., et al. (2011). The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the national institute on Aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 270–279. doi: 10.1016/j.jalz.2011.03.008

Alzheimer's Association. (2021). 2021 Alzheimer's disease facts and figures. Alzheimers Dement. 17, 327–406. doi: 10.1002/alz.12328

Antunes, M., and Biala, G. (2012). The novel object recognition memory: Frontiers in Neuroscience | www.frontiersin.org 14

Ashe, K. H. (2020). The biogenesis and biology of amyloid beta oligomers in the Alzheimer disease. Mol. Psychiatry 25, 1041–1050. doi: 10.1038/s41380-021-01249-0

Buchanan, H., Mackay, M., Palmer, K., Tothová, K., Katsur, M., Platt, B., et al. (2019). A novel crosslinking protocol stabilizes amyloid beta oligomers and object location behavioral testing in mice on a budget. J. Vis. Exp. 148, e51972. doi: 10.3389/fnins.2021.768646/full#supplementary-material

Cline, E. N., Cibis, I. A., Devi, L., Alldred, M. J., Ginsberg, S. D., and Ohno, M. (2010). Sex- and brain region-specific acceleration of beta-amyloidogenesis following behavioral stress in a mouse model of Alzheimer’s disease. Mol. Brain 3:34. doi: 10.1186/1756-6614-3-34

Dorostkar, M. M., Burgold, S., Filser, S., Barghorn, S., Schmidt, B., Anumala, U. R., et al. (2014). Immunotherapy alleviates amyloid-associated synaptic pathology in an Alzheimer’s disease mouse model. Brain 137( Pt 12), 3319–3326. doi: 10.1093/brain/awu280

Esparza, T. J., Zhao, H., Ciritto, J. R., Cairns, N. J., Bateman, R. J., Holtzman, D. M., et al. (2013). Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls. Ann. Neurol. 73, 104–119. doi: 10.1002/ana.23748

Feinberg, S. T., and Klein, W. L. (2011). The Abeta oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease. Neurobiol. Learn. Mem. 96, 529–543. doi: 10.1016/j.nblm.2011.08.003

Gandy, S., Simon, A. J., Steele, J. W., Lublin, A. L., Lah, J. J., Walker, L. C., et al. (2010). Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. Ann. Neurol. 68, 220–230. doi: 10.1002/ana.22052

Georganopoulou, D. G., Chang, L., Nam, J. M., Thaxton, C. S., Mufson, E. J., Klein, W. L., et al. (2005). Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer’s disease. Proc. Natl. Acad. Sci. U.S.A. 102, 2273–2276. doi: 10.1073/pnas.0409336102

Gibbs, E., Silverman, J. M., Zhao, B., Peng, X., Wang, J., Wellington, C. L., et al. (2019). A rationally designed humanized antibody selective for amyloid beta oligomers in Alzheimer’s disease. Sci. Rep. 9:9870. doi: 10.1038/s41598-019-46306-5

Giard, S. D., Baranger, K., Gauthier, C., Jacquet, M., Bernard, A., Escoffier, G., et al. (2013). Evidence for early cognitive impairment related to frontal cortical in the 5XFAD mouse model of Alzheimer’s disease. J. Alzheimers Dis. 33, 781–796. doi: 10.3233/JAD-2012-120982

Giard, S. D., Jacquet, M., Baranger, K., Migliorati, M., Escoffier, G., Bernard, A., et al. (2014). Onset of hippocampus-dependent memory impairments in 5XFAD transgenic mouse model of Alzheimer’s disease. Hippocampus 24, 762–772. doi: 10.1002/hipo.22267

Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., et al. (2013). Oligomer-directed ACU193 monoclonal antibody therapeutic for treatment of early Alzheimer’s disease. J. Prev. Alzheimers Dis. 6(Suppl. 1):S151.

Cohen, S. J., and Stackman, R. W. Jr. (2015). Assessing rodent hippocampal involvement in the novel object recognition task. A review. Behav. Brain Res. 285, 105–117. doi: 10.1016/j.bbr.2014.08.002

Colom-Cadena, M., Spires-Jones, T., Zetterberg, H., Blennow, K., Caggiano, A., DeKosky, S. T., et al. (2020). The clinical promise of biomarkers of synaptic damage or loss in Alzheimer’s disease. Alzheimers Res. Ther. 12:21. doi: 10.1186/s13195-020-00588-4

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnins.2021.768646/full#supplementary-material

Cummins, J. L., Lee, G., Zhong, K., Fonseca, J., and Taghva, K. (2021). Alzheimer’s disease drug development pipeline: 2021. Alzheimers Dement. 7:e12179. doi: 10.1002/trc2.12179

Denninger, J. K., Smith, B. M., and Kirby, E. D. (2018). Novel object recognition and object location behavioral testing in mice on a budget. J. Vis. Exp. 141:e58593. doi: 10.3791/58593

Devi, L., Alldred, M. I., Ginsberg, S. D., and Ohno, M. (2010). Sex- and brain region-specific acceleration of beta-amyloidogenesis following behavioral stress in a mouse model of Alzheimer’s disease. Mol. Brain 3:34. doi: 10.1186/1756-6614-3-54

Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., et al. (2021). The amyloid-beta pathway in Alzheimer’s disease. Mol. Psychiatry doi: 10.1038/s41386-021-01249-0

Henry Weiss, Rohan Chalasani, and Erika N. Cline for their assistance that helped make this study possible. We also would like to thank the Northwestern University Research Experiences for Undergraduates program for their support.
Hefti, F., Goure, W. F., Jerecic, J., Iverson, K. S., Walicke, P. A., and Krafft, G. A. (2013). The case for soluble Abeta oligomers as a drug target in Alzheimer's disease. *Trends Pharmacol. Sci.*, 34, 261–266. doi: 10.1016/j.tips.2013.03.002

Hillen, H., Barghorn, S., Striebinger, A., Labkovsky, B., Muller, R., Nimrichter, V., et al. (2010). Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies. *J. Neurosci.*, 30, 10369–10379. doi: 10.1523/jneurosci.5721-09.2010

Hsia, A. Y., Masliah, E., McConlogue, L., Yu, G. Q., Tatsuno, G., Hu, K., et al. (1999). Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. *Proc. Natl. Acad. Sci. U.S.A.*, 96, 3228–3233.

Huang, S., Tong, H., Lei, M., Zhou, M., Guo, W., Li, G., et al. (2017). Astrocytic glutamatergic transporters are involved in Abeta-induced synaptic dysfunction. *Brain Res.*, 1678, 129–137. doi: 10.1016/j.brainres.2017.10.011

Hubelt, S., and Adeli, H. (2013). EEG/MEG- and imaging-based diagnosis of Alzheimer's disease. *Rev. Neurosci.*, 24, 536–573. doi: 10.1515/reviewneuro-2013-0042

Investor Relations (2021). *FDA Grants Accelerated Approval for ADUHELM™ as the First and Only Alzheimer's Disease Treatment to Address a Defining Pathology of the Disease*. Cambridge, MA: Biogen.

Jack, C. R. Jr., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., et al. (2011). Introduction to the recommendations from the National Institute on Aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.*, 7, 257–262. doi: 10.1016/j.jalz.2011.03.004

Jawhar, S., Trawicka, A., Jenneckens, C., Bayer, T. A., and Wirths, O. (2012). Investor Relations (2021).

Lambert, M. P., Velasco, P. T., Chang, L., Viola, K. L., Fernandez, S., Lacor, P. N., et al. (2007). Monoclonal antibodies that target pathological assemblies of Abeta. *J. Neurochem.*, 100, 23–35. doi: 10.1111/j.1471-4159.2006.04157.x

Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Sengupta, U., Guerrero-Munoz, M. J., Kiritoshi, T., Neugebauer, V., et al. (2012). Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. *Sci. Rep.*, 2:700. doi: 10.1038/srep00700

Lesne, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., et al. (2006). A specific amyloid-beta protein assembly in the brain impairs memory. *Nature*, 440, 352–357. doi: 10.1038/nature04533

Lin, N., Gao, J., Mao, C., Sun, H., Lu, Q., and Cui, L. (2021). Differences in multimodal electroencephalogram and clinical correlations between early-onset Alzheimer's disease and frontotemporal dementia. *Front. Neurosci.*, 15:68705. doi: 10.3389/fnins.2021.687053

Mannusson, K., Sehlin, D., Syvans, S., Svedberg, M. M., Philipson, O., Soderberg, L., et al. (2013). Specific uptake of an amyloid-beta prototifibril-binding antibody-tracer in AbetaPP transgenic mouse brain. *J. Alzheimers Dis.*, 37, 29–40. doi: 10.3339/jad.130029

Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., and Beyreuther, K. (1985). Amyloid plaque core protein in Alzheimer disease and Down syndrome. *Proc. Natl. Acad. Sci. U.S.A.*, 82, 4245–4249.

Mathis, C. A., Wang, Y., Holt, D. P., Huang, G. F., Debnath, M. L., and Klunk, W. E. (2003). Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenezothiozoles as amyloid imaging agents. *J. Med. Chem.*, 46, 2740–2745. doi: 10.1021/jm030026b

McKchn, G. M., Knopman, D. S., Cherikow, H., Hyman, B. T., Jack, C. R. Jr., Kawash, C. H., et al. (2011). The diagnosis of dementia due to Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.*, 7, 263–269. doi: 10.1016/j.jalz.2011.03.005

McLean, D., Cooke, M. J., Wang, Y., Green, D., Fraser, P. E., George-Hyslop, P. S., et al. (2012). Anti-amyloid-beta-mediated positron emission tomography imaging in Alzheimer's disease mouse brains. *PLoS One.*, 7:e51958. doi: 10.1371/journal.pone.0051958

Mecca, A. P., Chen, M. K., O'Dell, R. S., Naganawa, M., Toyonaga, T., Godek, T. A., et al. (2020). In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET. *Alzheimers. Dement.*, 16, 974–982. doi: 10.1002/dz.21097

Meng, X., Li, T., Wang, X., Lv, X., Sun, Z., Zhang, J., et al. (2019). Association between increased levels of amyloid-beta oligomers in plasma and episodic memory loss in Alzheimer's disease. *Alzheimers Res. Therapy*, 11:89. doi: 10.1186/s13195-019-0535-7

Mirzaei, N., Shi, H., Oviatt, M., Doustast, J., Rentsendorj, A., Fuchs, D. T., et al. (2020). Alzheimer's retnopathy: seeing disease in the eyes. *Front. Neurosci.*, 14:921. doi: 10.3389/fnins.2020.00921

Monterey, M. D., Wei, H., Wu, X., and Wu, J. Q. (2021). The many faces of astrocytes in Alzheimer's disease. *Front. Neurosci.*, 15:619626. doi: 10.3389/fnins.2021.619626

Montoliu-Gaya, L., Strydom, A., Blenno, K., Zetterberg, H., and Ashton, N. J. (2021). Blood biomarkers for Alzheimer's disease in Down syndrome. *J. Clin. Med.*, 10:3639. doi: 10.3390/jcm10163639

Mucke, L., and Selkoe, D. J. (2012). Neurotoxicity of amyloid-beta protein: synaptic and network dysfunction. *Cold Spring Harb. Perspect. Med.*, 4:a006338. doi: 10.1101/cshperspect.a006338

Mucke, L., Masliah, E., Yu, G. Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., et al. (2000). High-level neuronal expression of abeta 1–42 in wild-type human amyloid protein precursor transgenic mice: synaptic toxicity without plaque formation. *J. Neurosci.*, 20, 4050–4058.

Mufson, E. J., Ward, S., and Binder, L. (2014). Prefibrillar tau oligomers in mild cognitive impairment and Alzheimer's disease. *Neurodegener. Dis.*, 13, 151–153. doi: 10.1159/000353687

Mundt, A. P., Winter, C., Mueller, S., Wuerfel, J., Tysiak, E., Schnorr, J., et al. (2009). Targeting activated microglia in Alzheimer's pathology by intraventricular delivery of a phagocytosable MRI contrast agent in APP23 transgenic mice. *Cold Spring Harb. Perspect. Med.*, 2:a006338. doi: 10.1101/cshperspect.a006338

Nandwana, V., Ryo, S.-R., Kishita, S. D., De, M., Chou, S. S., Prasad, P. V., et al. (2016). Engineered theranostic magnetic nanosstructures: role of composition and surface coating on magnetic resonance imaging contrast and thermal activation. *ACS Appl. Mater. Interfaces*, 8, 6953–6961. doi: 10.1021/acsami.6b01377
Nyborg, A. C., Moll, J. R., Wegryn, R. D., Havas, D., Hutter-Paier, B., Feuerstein, G. G., et al. (2013). In vivo and ex vivo imaging of amyloid-beta cascade aggregates with a Pronucleon peptide. J. Alzheimers Dis. 34, 957–967. doi: 10.3233/JAD-121207

Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., et al. (2006). Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129–10140. doi: 10.1523/JNEUROSCI.1202-06.2006

Oblak, A. L., Lin, P. B., Kotredes, K. P., Pandey, R. S., Garceau, D., Williams, H. M., et al. (2021). Comprehensive evaluation of the 5xFAD mouse model for preclinical testing applications: a model-AD study. Front. Aging Neurosci. 13:713726. doi: 10.3389/fnagi.2021.713726

Ohno, M., Chang, L., Tseng, W., Oakley, H., Citron, M., Klein, W. L., et al. (2006). Temporal memory deficits in Alzheimer’s mouse models: rescue by genetic deletion of BACE1. Eur. J. Neurosci. 23, 251–260. doi: 10.1111/j.1460-9568.2005.05451.x

Ou-Yang, M. H., and Van Nostrand, W. E. (2013). The absence of myelin Slemmon, J. R., Meredith, J., Guss, V., Andreasson, U., Andreasen, N., Zetterberg, H., et al. (2012). Measurement of Abeta1-42 in cerebrospinal fluid is influenced by matrix effects. J. Neurochem. 120, 325–333. doi: 10.1111/j.1471-4159.2011.07533.x

Silverman, J. M., Gibbs, E., Peng, X., Martens, K. M., Balducci, C., Wang, J., et al. (2018). A Rational structured epitope defines a distinct subclass of toxic amyloid-beta oligomers. ACS Chem. Neurosci. 9, 1591–1606. doi: 10.1021/acschemneuro.7b00469

Slemmon, J. R., Meredith, J., Guss, V., Andreasson, U., Andreasen, N., Zetterberg, H., et al. (2012). Measurement of Abeta1-42 in cerebrospinal fluid is influenced by matrix effects. J. Neurochem. 120, 325–333. doi: 10.1111/j.1471-4159.2011.07533.x

Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., et al. (2011). Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7, 280–292. doi: 10.1016/j.jalz.2011.03.003

Streit, W. J., Khoshbouei, H., and Bechmann, I. (2021). The role of microglia in sporadic Alzheimer’s disease. J. Alzheimers Dis. 79, 961–968. doi: 10.3233/JAD-201248

Suß, P., and Schlachetzki, J. C. M. (2020). Microglia in Alzheimer’s disease. Curr. Alzheimer Res. 17, 29–43. doi: 10.2174/1567205016666200320155234

Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., et al. (1991). Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572–580. doi: 10.1002/ana.410300411

Toledo, J. B., Xie, X. I., Trojanowski, J. Q., and Shaw, L. M. (2013). Longitudinal change in CSF Tau and Abeta biomarkers for up to 48 months in ADNI. Acta Neuropathol. 126, 659–670. doi: 10.1007/s00401-013-1151-4

Townsend, M., Shankar, G. M., Mehta, T., Walsh, D. M., and Selkoe, D. J. (2006). Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J. Physiol. 572(Pt 2), 477–492. doi: 10.1113/jphysiol.2005.037554

Velasco, P. T., Heffern, M. C., Sebolliea, A., Popova, I. A., Lacor, P. N., Lee, K. B., et al. (2012). Synapse-binding subpopulations of Abeta oligomers sensitive to peptide assembly blockers and scFv antibodies. ACS Chem. Neurosci. 3, 972–981. doi: 10.1021/nc300122k

Viola, K. L., and Klein, W. L. (2015). Amyloid beta oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis. Acta Neuropathol. 129, 183–206. doi: 10.1007/s00401-015-1386-3

Viola, K. L., Sbarboro, J., Sureka, R., De M., Bicca, M. A., Wang, J., et al. (2015). Towards non-invasive diagnostic imaging of early-stage Alzheimer’s disease. Nat. Nanotechnol. 10, 91–98. doi: 10.1038/nnano.2014.254

Wang, C., Xiong, M., Gratuze, M., Bao, X., Shi, Y., Andhey, P. S., et al. (2015). Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia. Neuron 109, 1657–1674.e7. doi: 10.1016/j.neuron.2021.03.024

Wipke, B. T., Wang, Z., Kim, J., McCarthy, T. J., and Allen, P. M. (2002). Dynamic visualization of a joint-specific autoimmune response through positron emission tomography. Nat. Immunol. 3, 366–372. doi: 10.1038/njur77

Xiao, C., Davis, P. J., Chauhan, B. C., Viola, K. L., Lacor, P. N., Velasco, P. T., et al. (2013). Brain transit and ameliorative effects of intranasally delivered anti-amyloid-beta oligomer antibody in 5xFAD mice. J. Alzheimers Dis. 35, 777–788. doi: 10.3233/JAD-122419

Zhang, M., Zhong, L., Han, X., Xiong, G., Xu, D., Zhang, S., et al. (2021). Brain and retinal abnormalities in the 5xFAD mouse model of Alzheimer’s disease at early stages. Front. Neurosci. 15:681831. doi: 10.3389/fnins.2021.681831

Zhang, T., Liao, Q., Zhang, D., Zhang, C., Yan, J., Ngetich, R., et al. (2021). Predicting MCI to AD conversation using integrated sMRI and rs-fMRI: machine learning and graph theory approach. Front. Aging Neurosci. 13:688926. doi: 10.3389/fnagi.2021.688926

Conflict of Interest: KV and WK are shareholders in Acumen Pharmaceuticals, Inc.